

**Elections to the
European Association of
Percutaneous Cardiovascular Interventions (EAPCI)
Elected positions 2016-2018**



GIULIO GUAGLIUMI, MD
Country : ITALY

Application for the following position in the EAPCI Board:
SECRETARY

Current position

Interventional Cardiologist at Cardiovascular Department, Ospedale Papa Giovanni XXIII, Bergamo, ITALY

Profession

- ☒ **Interventionalist.**
☐ Healthcare Professional (Nurse, Radiographer, Technician) working in PCI.
☐ Industry Professional.
☐ Other.

Additional Information

- ☒ **Fellow of the ESC**
☒ **EAPCI Member**
☒ **Member of a National Cardiac Society**
*If yes, specify: **Italian Society of Invasive Cardiology (GISE)***
☐ Member of an Interventional Working Group
If yes, specify:



General CV (as it pertains to PCI) – 300 words max

Dr. Giulio Guagliumi is leading the Research Program at Interventional Cardiology, Ospedale Papa Giovanni XXIII Bergamo, Italy. He was trained with Master in Interventional Cardiology at the Clinique Pasteur, Toulouse, France. He was awarded at Mayo Clinic and St. Mary Hospital, Rochester in imaging and coronary physiology assessment of vascular response to intracoronary stents. He has a long-standing interventional practice with research expertise in acute myocardial infarction, stent, vascular biology and intravascular imaging. He is fellow of the ESC and member of EAPCI since 2004, currently appointed to the Executive Board, co-chair for the scientific program in interventional cardiology at the ESC Congress, member of the scientific committee at TCT, TCTAP, PCR Asia. He has ongoing scientific collaboration with Emory University (Atlanta), MIT (Boston), Wakayama University (Japan), Harbin University (China). Fellow of the Italian Society of Invasive Cardiology since 2003, he was the Scientific Director of the GISE Congress in 2008-2009 and President of the Italian Society in 2009-2011. Principal investigator and member of the Steering Committee in multiple prospective, randomized, multicenter studies in primary-PCI, stent, DES, intracoronary imaging (IVUS, OCT). Author of 204 peer reviewed scientific manuscripts, published across all prestigious cardiology journals, including New England Journal, Circulation, JACC, European Heart Journal and Lancet. He has 285 Abstracts accepted at the main international scientific conferences. Reviewer of: Circulation, Circ Interv, JACC, JACC Interv. JACC Imaging, Eur H Journal, Nature Cardiovascular Medicine, Eurointervention. His the co-author of imaging chapters in multiple textbooks, including the Interventional Cardiology Textbook-six and seventh edition edited by Eric J. Topol, MD and Paul S. Teirstein, MD. In 2014 he was listed by Thomson Reuters among the most influential researcher in the last ten years from inCites and the Web of Science.

Previous experience in EAPCI, ESC or your National Bodies


- ESC, member of the DES-FOCUS panel (2007)
- Scientific Director of the GISE Congress in 2008 and 2009
- President) of the Italian Society of Invasive Cardiology (GISE) - 2010 and 2011
- Co-chair EAPCI Program Scientific Committee for the ESC Congress 2012-2014: Expert Chair of the same Committee in 2015
- Executive Board of EAPCI 2014-2016

If you have been involved in EAPCI in the past, please specify the position(s) as well as the relevant date(s)

Country champion of the European Stent for Life project in 2010-2014, to correct inequalities in access to primary-PCI at Italian regional level (target Sicily, Campania, Puglia, Piemonte, Veneto). Promoter at the EAPCI level of the joint initiative with the largest Japanese society (CVIT). Co-shared meetings at EUROPCR and CVIT Congresses.

Publications in the field of PCI (max 10)

1. Randomized Study with the Sirolimus-Coated BxVelocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. **N Engl J Med. 2002**;346:1773-80.
2. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. **N Engl J Med. 2002** ;346:957-66.
3. Localized Hypersensitivity and late coronary thrombosis secondary to a Sirolimus Eluting Stent **Circulation 2004, 109: Fast Track Special Report 701-705**
4. Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice. One-Year Follow-Up of the e-Cypher Registry. **Circulation. 2006 Mar 13; 113:1434-41**
5. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. **N Engl J Med. 2009 May 7;360(19):1946-59**
6. Examination of the in-vivo mechanisms of late drug-eluting stent thrombosis. Findings from Optical Coherence Tomography and Intravascular Ultrasound imaging. **JACC Cardiovasc Interv 2012; Jan 5 (1) 12-20. CME article.**
7. Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared with Bare Metal Stents in Acute Myocardial Infarction: Optical Coherence Tomography Substudy of the HORIXZONS-AMI. **Circulation 2011 Jan 10; 123.274-28**
8. Mechanisms of Atherothrombosis and Vascular Response to Primary Percutaneous Coronary Intervention in Women Versus Men With Acute Myocardial Infarction. **JACC Cardiovascular Interventions, Volume(s) 7, 13-Aug-2014, 958-968**
9. Eroded versus ruptured plaques at the culprit site of STEMI: in vivo pathophysiological features and response to primary PCI. **JACC Cardiovasc Imaging 2015.Apr 8. Pii S1936-878X(15)00180-1. Epub ahead of print.**
10. Subclinical carotid atherosclerosis and early vascular aging from long-term low-dose ionizing radiation exposure: a genetic, telomere, and vascular ultrasound study in cardiac catheterization laboratory staff. **JACC Cardiovasc Interv. 2015 Apr 20;8(4):616-27. doi: 10.1016/j.jcin.2014.12.233.**



What would you like to achieve if you were elected?

- 1)** Strength the EAPCI "identity " across the interventional community (why interventionalist must be part of?), the industry (why we should cooperate with EAPCI?) and the health care providers (data collection for better services)
- 2)** Promoting the role of EAPCI as incubator of new ideas/knowledge transfer in interventional cardiology (define a path for), and higher level research organization, designing large clinical trials (use existing core competencies to cooperate and attract resources- ie EU commission, Institute for Innovation Policy, Industries- to be reinvested in education and formation
- 3)** Reinforce relationship and cooperation with growing realities and national societies

If you were elected, how do you envisage organizing yourself to accommodate this very demanding additional commitment?

I've already duties and time spent inside the EAPCI board and committees. I'm very familiar with flying everywhere, with stable international link and connection.

I'll count on some more local secretarial support and strict cooperation with the new president elect for sharing duties.



Recommendation letter(s)

A recommendation letter from the Interventional Working Group or National Society is mandatory for all positions

(see below)

**Elections to the
European Association of
Percutaneous Cardiovascular Interventions (EAPCI)
Elected positions 2016-2018**



Società Italiana di Cardiologia Invasiva

Via Conservatorio, 22 20122 Milano, Tel. 02-77297541 Fax 02-772940 Email:gisemail@tin.it

Milan, November 25 2015

Recommendation letter for EAPCI Elected Position 2016-2018

Presidente:

Giuseppe Musumeci

Past President:

Sergio Berti

Consiglieri:

Alessio La Manna
Ugo Limbruno
Alfredo Marchese
Ciro Mauro
Fabio Tarantino

Rappresentante Soci

Aggregati:

Beatrice Magro

The Italian Society of Interventional Cardiology - GISE is pleased and honored to recommend Dr. Giulio Guagliumi for the position of EAPCI- Secretary at the upcoming 2016-2018 elections.

Dr. Guagliumi is a Fellow of GISE and Fellow of the ESC since 2004. He was the Scientific Director of the Italian Congress of Invasive Cardiology in 2008 and 2009, then President Elected of the Italian Society of Invasive Cardiology in the years 2009-2011.

Under his presidency he promoted and launched on behalf of GISE clinically relevant investigator sponsored Trials, including OCTAVIA, assessing the gender difference in women and man presenting with STEMI (PI G. Guagliumi JACC Interv. 2014; 7:958-68), and Matrix [PI M. Valgimigli Lancet 2015;385(9986):2465-76] comparing femoral and radial approach in STEMI. In addition he was acting as champion of the Stent for Life project at the Italian level, organizing and launching STEMI network initiatives in regions (Sicily, Campania, Puglia, Piemonte, Veneto) with inequalities in access, to guarantee to all patients the primary PCI treatment. The data monitoring of the STEMI activity in the following years, documented the efficacy of the project.

Finally, dr. Guagliumi promoted and executed a first global data collection on risks of the Cath Lab staff to continuous low radiation exposure. The project, named Healthy Cath Lab Study, collected multi-modalities clinical, ultrasound, blood, biomarkers, telomeres data in combination with operator and staff radiation doses (M. Andreassi , JACC Interv 2015;8:616-27).

Dr. Guagliumi was increasing during his presidential time the Italian membership to the EAPCI, becoming one leading group of the Society.

Sincerely Yours,

Giuseppe Musumeci
President
Italian Society of Interventional Cardiology -GISE

